Gilead Science公司比收入估计数高,提出了2026年的指导意见,并提升了其红利,同时通过购置了7.8B美元,促进了肿瘤学的增长。 Gilead Sciences beat earnings estimates, raised 2026 guidance, and boosted its dividend, while advancing its oncology growth via a $7.8B acquisition.

吉利德科学公司报告了强的第四季度收益,以1.86美元的每股收益和793亿美元的收入超过预期,同比增长4.7%,并将2026年全年每股收益预期提高到8.458.85美元. Gilead Sciences reported strong Q4 earnings, beating estimates with $1.86 EPS and $7.93 billion in revenue, up 4.7% year-over-year, and raised its 2026 full-year EPS guidance to $8.45–8.85. 该公司宣布季度股息为每股0.82美元,高于0.79美元,年收益为2.2%。 The company announced a quarterly dividend of $0.82 per share, up from $0.79, with a 2.2% annual yield. Jefferies以180美元的价格目标将Gilead升级为Buy, Jefferies upgraded Gilead to Buy with a $180 price target, citing positive momentum and a 15.7% drop in short interest. 机构利益增加,Amundi的股权增加到1 047万股,而Franklin Resources将其持有量减少了0.8%。 Institutional interest grew, with Amundi increasing its stake to 10.47 million shares, while Franklin Resources reduced its holding by 0.8%. 股票交易额约为146美元,市场上限为1812.5亿美元,低位贝塔为0.37美元。 The stock, trading around $146, has a market cap of $181.25 billion and a low beta of 0.37. Gilead正在通过购置78亿美元的Arcellx公司来追求增长,目标是肿瘤学和CAR-T进步。 Gilead is pursuing growth through its $7.8 billion acquisition of Arcellx, targeting oncology and CAR-T advancements.